Participant flow

First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin · Source last updated 2022-01-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Necitumumab + Pemetrexed + Cisplatin Necitumumab: 800 milligrams (mg) (absolute dose) on Days 1 and 8 of every 3-week cycle. Pemetrexed: 500 mg/square meter (mg/m2) intravenous (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles. Cisplatin: 75 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles.

   id

   FG000

   title

   Necitumumab + Pemetrexed + Cisplatin

2. description

   Pemetrexed + Cisplatin Pemetrexed: 500 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles. Cisplatin: 75 mg/m2 I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles.

   id

   FG001

   title

   Pemetrexed + Cisplatin

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         1

      type

      Adverse Event

   2. reasons

      1. group Id

         FG000

         num Subjects

         46

      2. group Id

         FG001

         num Subjects

         39

      type

      Progressive Disease

   3. reasons

      1. group Id

         FG000

         num Subjects

         9

      2. group Id

         FG001

         num Subjects

         6

      type

      Lost to Follow-up

   4. reasons

      1. group Id

         FG000

         num Subjects

         5

      2. group Id

         FG001

         num Subjects

         5

      type

      New Anti-Cancer Therapy

   5. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         0

      type

      Medical Decision

   6. reasons

      1. group Id

         FG000

         num Subjects

         17

      2. group Id

         FG001

         num Subjects

         19

      type

      Withdrawal by Subject

   7. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         1

      type

      Global Study End

   8. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         1

      type

      Sponsor's Decision

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         315

      2. group Id

         FG001

         num Subjects

         318

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         304

      2. group Id

         FG001

         num Subjects

         312

      type

      Received at Least 1 Dose of Study Drug

   3. achievements

      1. group Id

         FG000

         num Subjects

         236

      2. group Id

         FG001

         num Subjects

         246

      type

      Death Due to Any Cause

   4. achievements

      1. group Id

         FG000

         num Subjects

         236

      2. group Id

         FG001

         num Subjects

         246

      type

      COMPLETED

   5. achievements

      1. group Id

         FG000

         num Subjects

         79

      2. group Id

         FG001

         num Subjects

         72

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

Completers included participants who died from any cause and participants who were alive and on study at conclusion however were off treatment.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice